trending Market Intelligence /marketintelligence/en/news-insights/trending/aykj91-JXKgbFYrMOUjf2Q2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Sandu Pharmaceuticals fiscal Q2 profit falls YOY

Blog

So, the data lakehouse is now officially a ‘thing’ – what is it and why should you care?

Blog

Industry Top Trends 2021: Oil and Gas

Blog

Charter, DIRECTV and Comcast rank as the top 'RSN-friendly' MVPDs

Industry Top Trends 2021: Metals and Mining


Sandu Pharmaceuticals fiscal Q2 profit falls YOY

Sandu Pharmaceuticals Ltd. said its normalized net income for the fiscal second quarter ended Sept. 30 was 4 Indian paise per share, a decrease of 80.3% from 19 paise per share in the year-earlier period.

Normalized net income, which excludes unusual gains or losses on a pre- and after-tax basis, was 266,250 rupees, a decline of 80.2% from 1.3 million rupees in the year-earlier period.

The normalized profit margin dropped to 0.3% from 1.4% in the year-earlier period.

Total revenue increased 7.2% year over year to 104.6 million rupees from 97.6 million rupees, and total operating expenses climbed 9.1% from the prior-year period to 100.2 million rupees from 91.9 million rupees.

Reported net income decreased 93.2% from the prior-year period to 100,000 rupees, or 1 paise per share, from 1.5 million rupees, or 21 paise per share.

As of Nov. 13, US$1 was equivalent to 66.19 Indian rupees.